Key clinical point: The dual mTORC1-2 inhibitor Rapalink-1 reduced tumor growth in prostate cancer cells in a mouse model.

Major finding: Treating mice with Rapalink-1 every 6 days resulted in significantly reduced tumor growth and decreased expression of CD44 based on tumor size and Ki67 staining on lysates-matched tumor sections.

Study details: The data come from a molecular analysis of breast and prostate cancer bone metastasis using patient-derived xenografts (PDX) from 5 prostate cancer patients and 4 breast cancer patients and an organoid-based drug screen.

Disclosures: The study was supported by Grant # UL2015-7599 (KWF), # 169352 (SNSF), and # 179265 (SNSF) awarded to study coauthors. The researchers had no financial conflicts to disclose.